Publicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (45)

2020

  1. Bioequivalence Evaluation of Three Pediatric Oral Formulations of Bilastine in Healthy Subjects: Results from a Randomized, Open Label, Crossover Study

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 45, Núm. 2, pp. 265-272

2018

  1. Bioavailability of two oral fentanyl transmucosal formulations in healthy volunteers: An open-label, crossover, randomised study

    Revista de la Sociedad Espanola del Dolor, Vol. 25, Núm. 4, pp. 222-227

2014

  1. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

2013

  1. Effect of glucose concentration on the stability of daptomycin in peritoneal solutions

    Peritoneal Dialysis International

  2. Oral availability of bilastine

    Clinical Drug Investigation, Vol. 33, Núm. 5, pp. 375-381

2010

  1. A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma

    Cancer Gene Therapy, Vol. 17, Núm. 12, pp. 837-843

  2. Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: Application to a clinical pharmacokinetic study

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 51, Núm. 4, pp. 875-881

2008

  1. Adverse effects and interactions of the new antibiotics active against Gram-positive cocci

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. SUPPL. 2, pp. 69-76

  2. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers

    Arzneimittel-Forschung/Drug Research, Vol. 58, Núm. 6, pp. 283-287

  3. Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers

    International Journal of Antimicrobial Agents

  4. Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers

    Clinical Drug Investigation, Vol. 28, Núm. 3, pp. 139-147

  5. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

    Enfermedades Infecciosas y Microbiologia Clinica

2007

  1. Detection and incidence of drug-induced agranulocytosis in hospital: A prospective analysis from laboratory signals

    European Journal of Clinical Pharmacology, Vol. 63, Núm. 3, pp. 221-228

  2. Fentanilo. Sistema terapéutico transdérmico y características de las distintas formulaciones

    DOLOR, Vol. 22, Núm. 4, pp. 195-205

  3. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: A phase I study

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 1, pp. 51-60

  4. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype

    Pharmacological Research, Vol. 55, Núm. 2, pp. 122-130

  5. Pharmacology of azoles

    Revista Iberoamericana de Micologia, Vol. 24, Núm. 3, pp. 223-227

  6. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  7. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in health subjects after intravenous and oral administration of racemic tramadol

    Biopharmaceutics and Drug Disposition, Vol. 28, Núm. 1, pp. 19-33

2006

  1. A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers

    European Journal of Clinical Pharmacology, Vol. 62, Núm. 10, pp. 849-854